Trusted Resource for Clinical Trials, Protocols & Progress
Ethical Considerations in Early Termination Ethical Considerations in Early Termination of Clinical Trials Introduction: Ethics at the Core of Trial Oversight Early termination of clinical trials based on pre-specified stopping rules is both a scientific and ethical decision. While stopping may protect participants from harm or allow earlier access to effective treatments, it may also…
Communicating Stopping Decisions to Sites Best Practices for Communicating Stopping Decisions to Clinical Trial Sites Introduction: The Importance of Clear Communication When pre-specified stopping rules are triggered in a clinical trial, timely and transparent communication with investigator sites is essential. Sites serve as the primary interface with participants, and unclear or delayed communication may compromise…
Ethical Considerations in DMC Decisions Ethical Considerations in Data Monitoring Committee Decisions Introduction: Ethics as the Foundation of DMC Decisions Data Monitoring Committees (DMCs) are entrusted not only with statistical oversight but also with profound ethical responsibilities in clinical trials. Their decisions—whether to continue, modify, or terminate a trial—must balance patient safety, scientific integrity, and…
Documenting Re-Consent for Protocol Amendments How to Properly Document Re-Consent During Protocol Amendments Introduction to Re-Consent Informed consent is not a one-time event. In clinical trials, whenever a protocol amendment introduces changes that impact participant rights, safety, or understanding of trial procedures, re-consent becomes a mandatory ethical and regulatory requirement. Re-consent ensures participants remain fully…
Read More “Documenting Re-Consent for Protocol Amendments” »
When and Why Re-Consent Is Required in Clinical Trials Understanding When and Why Re-Consent Is Required in Clinical Trials Informed consent is not a one-time event. As clinical trials evolve, certain circumstances may necessitate re-consenting the participant. This process—known as re-consent—is vital to maintaining transparency, ethical integrity, and regulatory compliance. In this guide, we explain…
Read More “When and Why Re-Consent Is Required in Clinical Trials” »
GCP and Regulatory Guidelines on Re-Consent in Clinical Trials Understanding GCP and Regulatory Requirements for Re-Consent in Clinical Trials Re-consent is a crucial component of ethical clinical trial conduct, ensuring that participants remain fully informed throughout their trial journey. As per global Good Clinical Practice (GCP) standards and local regulatory authorities like USFDA and CDSCO,…
Read More “GCP and Regulatory Guidelines on Re-Consent in Clinical Trials” »
Revising Informed Consent for Protocol Amendments in Clinical Trials How to Revise Informed Consent Following Protocol Amendments in Clinical Trials In the lifecycle of a clinical trial, changes to the protocol are common—whether due to safety findings, scientific advancements, regulatory updates, or operational needs. When such amendments affect the rights, safety, or well-being of participants,…
Read More “Revising Informed Consent for Protocol Amendments in Clinical Trials” »
Re-Consent Procedures in Clinical Trials: Ensuring Continuous Ethical Participation Maintaining Ethical Engagement: Re-Consent Procedures in Clinical Trials Clinical trials are dynamic processes where new information, evolving risks, or protocol amendments may impact participant understanding or willingness to continue. Re-consent procedures ensure that participants remain informed, empowered, and ethically engaged throughout their research journey. Conducting re-consent…
Read More “Re-Consent Procedures in Clinical Trials: Ensuring Continuous Ethical Participation” »
